CA
NZ
UK
AU
IND
US
Atea Pharmaceuticals reportedEarnings Per Shareof $-0.41 for Q2, outpacing the consensus estimate of $-0.57, while its Phase 3 C‑BEYOND trial met both primary and secondary endpoints, showcasing an eight‑week regimen for non‑cirrhotic patients. The earnings beat and trial validation sharpen the company’s growth narrative, …
BioStem Technologies, Inc. (OTC: BSEM) is a biotechnology firm valued at $73 million with $6.96 million in cash and equivalents and 17.8 million shares outstanding. The company announced second‑quarter 2026 net revenue of $7.9 million, a 29% jump from the prior quarter’s $6.1 million, …
Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a biopharmaceutical company focused on oncology, announced that its global Phase 3 clinical study, REZILIENT3, achieved its primary goal of improving patient outcomes. The interim analysis demonstrated a clear benefit for individuals receiving zipalertinib together with standard platinum‑based chemotherapy …
AARP's latest report highlights a stark reality for American seniors: brand-name drug prices in the U.S. rose 81% since their market launch, while prices for similar medications dropped 13% across 19 comparable countries. This data comes at a critical moment as the federal subsidy …
Neogen (NASDAQ:NEOG) shares are trading little changed in pre-market trading Thursday, up 1.57% to $11.64, as investors digest recent 13F filings showing mixed institutional activity. Sei Investments boosted its stake by 69.1% in the first quarter, while Bank of America trimmed its position by …
Omeros (NASDAQ:OMER) shares are surging in pre-market trading Thursday, up 20.82% to $16.56, after the company posted aBlowoutsecond-quarter 2026 earnings surprise driven by its newly launched rare-disease drug YARTEMLEA. Revenue reached $28.5 million, beating the $12.7 million estimate by 124.79%, while adjusted EPS of …
Aveanna Healthcare (NASDAQ:AVAH) shares are trading higher in pre-market action Thursday, up 11.50% to $10.09, extending Wednesday's more modest 1.12% regular-session gain as investors continue to digest the company's strong second-quarter results. Adjusted EPS of $0.18 beat estimates of $0.13, withRevenuerising 15.9% year-over-year to …
CorMedix (NASDAQ:CRMD) shares are trading higher in pre-market action Thursday, up 10.42% to $7.84, after the company reported second-quarter 2026 results and raised its full-year Adjusted EBITDA guidance. Consolidated revenue and grant income reached $101.9 million for the quarter, with net income of $26.0 …
Cullinan Therapeutics (NASDAQ:CGEM) shares are trading up 13.27% in pre-market action Thursday to $22.20, extending Wednesday's after-hours surge of more than 14% after partner Taiho Oncology's global Phase 3 REZILIENT3 trial met its primary endpoint of progression-free survival at a planned interim analysis. The …
Lumexa Imaging Holdings (NASDAQ:LMRI) shares are pulling back in pre-market trading Thursday, down 2.90% to $11.39, giving back a portion of Wednesday's after-hours rally as investors digest second-quarter results more critically this morning. The company reported adjusted EPS of $0.20, in line with consensus, …
Please wait processing your request...